Company Overview

Vystar Corporation (OTC: VYST) is a U.S.-based holding company operating in the biotechnology, medical device, and health technology sectors. The company’s stated focus is the development, acquisition, and commercialization of technologies aimed at improving human health, particularly in air purification, wound care, and medical treatment solutions. Vystar operates primarily through subsidiaries and controlled business units rather than a single integrated operating platform.

The company’s business model emphasizes identifying under-commercialized or emerging health technologies and advancing them toward broader market adoption. Vystar Corporation traces its origins to earlier-stage biotechnology ventures and has evolved through multiple restructurings, asset acquisitions, and strategic pivots. Public disclosures indicate that the company remains in a development and early commercialization phase, with limited recurring revenue compared to larger, established healthcare firms.

Business Operations

Vystar Corporation conducts operations primarily through RxAir Global, a subsidiary focused on ultraviolet-C (UV-C) air purification systems designed for medical, commercial, and public indoor environments. These systems are marketed for their ability to reduce airborne pathogens, including bacteria and viruses, in healthcare facilities, schools, offices, and transportation settings. Revenue generation is primarily tied to product sales, pilot installations, and distribution agreements related to these air purification technologies.

In addition to air purification, Vystar has disclosed involvement in biomedical and wound-care-related assets, including technologies intended to support tissue regeneration and infection control. However, public filings indicate that some of these initiatives remain in development or limited commercialization stages. Information regarding long-term contracts, large-scale manufacturing, or material joint ventures is limited, and certain operational details remain inconclusive based on available public sources.

Strategic Position & Investments

Strategically, Vystar Corporation positions itself as an incubator and consolidator of health-focused technologies with potential applications in infection prevention and patient care. Growth initiatives have centered on expanding the market reach of RxAir Global products, pursuing regulatory and institutional acceptance, and seeking strategic partnerships with distributors and healthcare providers. The company has publicly emphasized organic growth and targeted acquisitions rather than large-scale capital-intensive expansion.

Vystar has announced investments in early-stage medical technologies and intellectual property, though not all have progressed to material revenue contribution. The company’s disclosures reflect an ongoing evaluation of emerging healthcare technologies, particularly those aligned with heightened global awareness of air quality and infection control. Some announced initiatives and portfolio assets lack sufficient publicly available performance data, and their commercial impact cannot be fully verified.

Geographic Footprint

Vystar Corporation is headquartered in the United States, with its principal operations and corporate management based domestically. The company’s primary market focus remains North America, particularly the U.S. healthcare, education, and commercial real estate sectors where air quality solutions are in demand.

Internationally, Vystar has indicated intentions to pursue global distribution opportunities, including potential sales channels in Europe and Asia-Pacific through partners or resellers. However, publicly available information suggests that international operations are limited in scale, and there is no evidence of significant overseas manufacturing facilities or standalone foreign subsidiaries as of the most recent disclosures.

Leadership & Governance

Vystar Corporation is led by executives with backgrounds in business development, technology commercialization, and corporate restructuring. Leadership has articulated a strategic vision focused on acquiring promising health technologies and guiding them through regulatory, manufacturing, and market-entry challenges. The company operates with a relatively small executive team compared to larger public healthcare companies.

Key executives include:

• Josh Gottesman – Chief Executive Officer
• Steve Rotman – Chairman of the Board
• Jim McGovern – Chief Financial Officer

Governance is overseen by the board of directors, with management responsible for strategic execution and capital allocation. While leadership has outlined long-term growth objectives, the company’s limited operating history at scale means execution risk remains a material consideration based on publicly available information.